Financial Performance - Net revenues for Q4 2024 reached a record 60.7million,anincreaseof10.0 million, or 20%, compared to Q4 2023[4] - Total net revenues for the year 2024 were 224.3million,anincreaseof41.2 million, or 23%, over 2023[4] - Net income for Q4 2024 was 4.3million,or0.10 per diluted share, a 24% increase from Q4 2023[4] - Net income attributable to Viemed Healthcare, Inc. for the year ended December 31, 2024, was 11,265thousand,representinga9.910,243 thousand in 2023[13] - Basic net income per share for the year ended December 31, 2024, was 0.29,upfrom0.27 in 2023[13] EBITDA and Cash Flow - Adjusted EBITDA for the year 2024 was a record 51.1million[4]−AdjustedEBITDAfortheyearendedDecember31,2024,was51,107 thousand, compared to 43,064thousandin2023,reflectingan18.711.6 million, down from 21.7millionin2023[4]−CashflowsfromoperatingactivitiesfortheyearendedDecember31,2024,were39,089 thousand, down from 45,212thousandin2023[15]−Netcashprovidedbyoperatingactivitiesdecreasedto39,089,000 in 2024 from 45,212,000in2023,adeclineof13.511,639,000, down from 21,707,000in2023,representingadecreaseof46.3224,257 thousand, a 22.6% increase from 183,008thousandin2023[13]−Revenuefromventilatorrentals(non−invasiveandinvasive)roseby15.1124,577,000, accounting for 55.6% of total revenue in 2024[22] - Other home medical equipment rentals saw a significant increase of 27.0%, reaching 48,651,000in2024[22]−Equipmentandsupplysalesgrewby19.930,896,000, representing 13.7% of total revenue in 2024[22] - Service revenues surged by 88.8%, totaling 20,133,000in2024,upfrom10,665,000 in 2023[22] Patient Count and Market Expansion - The ventilator patient count increased to 11,795, a 14% increase year-over-year[4] - The PAP therapy patient count rose to 21,338, a 43% increase year-over-year[4] - The company plans to ramp up its sales force to penetrate the underserved market for non-invasive ventilation and complementary services[5] Future Projections - The company expects net revenue for 2025 to be in the range of 254millionto265 million[4] - Adjusted EBITDA for 2025 is expected to be between 54millionand58 million[4] Investment and Cash Management - Net cash used in investing activities for the year ended December 31, 2024, was (30,699)thousand,comparedto(52,113) thousand in 2023, indicating improved cash management[15] - The company reported a net increase in cash and cash equivalents of 4,701thousandfortheyearendedDecember31,2024,comparedtoadecreaseof(4,075) thousand in 2023[15] - The company invested 37,771thousandinpropertyandequipmentduringtheyearendedDecember31,2024,comparedto26,093 thousand in 2023, indicating ongoing expansion efforts[15] Shareholder Information - The weighted average number of diluted shares outstanding increased to 40,805,085 for the year ended December 31, 2024, from 40,378,922 in 2023[13]